Skip to content

Evolution of RBD in PD

Evolution of REM Sleep Behavior Disorder in Parkinson's Disease Patients RBD Diagnosed Three Years Earlier

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03047408
Enrollment
50
Registered
2017-02-09
Start date
2017-02-28
Completion date
2019-06-30
Last updated
2017-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease, REM Sleep Behavior Disorder

Keywords

REM Sleep Behavior Disorder, Parkinson's Disease, REM sleep without Atonia

Brief summary

About 60% of Parkinson's Disease (PD) patients have REM sleep Behavior Disorder (RBD), a parasomnia characterized by partial or complete loss of REM sleep muscle atonia and dream-enacting behaviors, usually associated to vivid dreams. The REM Sleep without atonia is the polysomnographic hallmark of RBD, and its quantification is necessary for the diagnosis. RBD in PD is believed to be a marker of a more widespread degenerative process and a marker of malignant phenotype. Therefore, PD patients with RBD (PD-RBD) are more severely impaired in both motor and non-motor domains, compared to those without RBD, with an increased risk of dementia. However, little is know about the relationship between the evolution of RBD, clinic and video-polysomnographic, and the progression of PD. Besides, an improvement of RBD symptoms is anecdotally reported in PD patients over time. Longitudinal evaluation of RBD in PD, assessed by questionnaires, led to controversial results, but so far, no longitudinal vPSG study has been performed in PD-RBD population. Thus, the main objective of this study is to longitudinally evaluate clinical and video-polysomnographic features of RBD, including measure of REM Sleep without atonia, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.

Detailed description

Type of study: longitudinal study, interventional, cross-sectional; Number of centres: 1 (Clermont-Ferrand) Patients: patients with Parkinson's Disease associated with REM sleep behavior disorder (PD-RBD) having already underwent video-polysomnography recording, clinical and neuropsychological evaluation in clinical setting or in the study RBHP 2013 DURIF at least three years ago. Study performance: This study will be developed in two phases: * Phase 1 (Day 0): * Verify inclusion criteria, receive informed and written consent; * Demographic and clinical characteristics; * Neurological evaluation: RBD (RBD severity scale), motor symptoms (Unified Parkinson's Disease Rating Scale, Hoeh et Yahr scale), orthostatic hypotension (Scale for outcomes in PD autonomic questionnaire), behavioral disorders hyper-dopaminergic and hypo-dopaminergic (Ardouin Scale of Behavior in Parkinson's Disease), impulsivity (Test Kirby and Stop signal reaction time) * Dreams contents: all patients will receive 3-weeks dream diary; * vPSG recording; * Self-assessment questionnaires: Non-motor symptoms Questionnaire, Epworth sleepiness scale, Urgency premeditation perseverance and sensation seeking test, Aggressive questionnaire, and the Hospital Anxiety and Depression Rating Scale * Phase 2 (+1day): Neuropsychological assessment of: * Cognitive function, namely executive functions, visuo-spatial functions, visuo-perceptive functions (Mini mental state examination, California Verbal Learning Test, verbal fluency test, Modified Wisconsin Card Sorting Test, test de Stroop, Digit span, Visual Object and Space Perception Battery, Luria motor sequences, Rey-Osterrieth complex figure) * Limbic functions: emotion recognition (Ekman test), apathy (Lille Apathy Rating Scale); * Impulsivity and decision-making (Iowa Gambling test).

Interventions

the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Masking description

open

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients with clinically confirmed idiopathic Parkinson's Disease, according to the United Kingdom Parkinson Disease Bran Bank criteria, associated with RBD, diagnosed according to the International Classification of Sleep Disorders third edition, that have been already enrolled in the study RBHP 2013 DURIF, or that have already underwent vPSG recording,clinical and neuropsychiatric evaluation in clinical setting; * Male and female aged between 45 to 85 years old; * All patients are volunteers and have given written informed consent; * All patients are able to understand and to perform all tests included in this protocol; * User-friendly in French language, both oral and written

Exclusion criteria

* Patients with neurological diseases other than PD; * Patients with psychiatric comorbidities (hallucinations, psychosis) according to the DSM-5. * Patients with Obstructive Sleep Apnea Syndrome (Apnea/hypopnea index \>15/h); * Patients in guardianship or tutorship; * Patients enrolled exclusively in another study.

Design outcomes

Primary

MeasureTime frame
presence of REM sleep Behavior Disorder confirmed during the video polysomnographyat day 0

Secondary

MeasureTime frame
The Unified Parkinson disease Rating scale scoreat day 0
The behavioral disorders measured by the Ardouin Scale of Behavior in Parkinson's Disease scoreat day 0
- The Orthostatic hypotension measured by the Scale for outcomes in PD- autonomic questionnaireat day 0
The impulsivity measured by the Test of Kirby scoreat day 0
The impulsivity measured by the Stop signal reaction time scoreat day 0
The Hoehn and Yahr scale scoreat day 0
The Non-motor symptoms Questionnaire scoreat day 0
The Epworth sleepiness scale scoreat day 0
The Urgency premeditation perseverance and sensation seeking testat day 0
The Aggressive questionnaire scoreat day 0
The Hospital Anxiety and Depression Rating Scaleat day 0
The REM sleep Behavior Disorder severity measured by the REM sleep Behavior Disorder scaleat day 0
The Mini mental state examination scoreat day 1
The California Verbal Learning Test scoreat day 1
The fluency verbal test scoreat day 1
The Modified Wisconsin Card Sorting Testat day 1
The Stroop scoreat day 1
The Empan test scoreat day 1
The Visual Object and Space Perception Battery test scoreat day 1
The Luria motor sequencesat day 1
The Rey-Osterrieth complex figureat day 1
The Lille Apathy Rating Scale scoreat day 1
The Iowa Gambling test scoreat day 1
The dream contentat day 0

Countries

France

Contacts

Primary ContactPatrick LACARIN
placarin@chu-clermontferrand.fr0473751195

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026